Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Study of Milrinone in Babies With Persistent Pulmonary Hypertension of the Newborn

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age \> 34 weeks~* Post-natal age \< 10 days~* Hypoxemia defined by: Oxygenation Index (OI) \>15 (Mean Airway Pressure x Fraction of Inspired Oxygen (FiO2) x 100 /PaO2) as drawn from two post-ductal arterial blood gas samples (in-dwelling arterial catheter) taken at least 15 minutes apart. OR mechanically ventilated and with \>75% FiO2 for \>6 hours while on iNO~* Absence of congenital heart disease based on a two-dimensional echocardiogram and/or clinical assessment~* An in-dwelling arterial catheter to facilitate painless sampling~* Currently on iNO or plan to start iNO before enrollment~Exclusion Criteria:~* Lethal non-cardiac congenital anomalies including diaphragmatic hernia~* Clinically apparent bleeding; thrombocytopenia \<30,000 or other laboratory evidence of coagulopathy~* Currently on extracorporeal membrane oxygenation (ECMO)or plan to initiate ECMO within 2 hours of enrollment

- Gender: ALL
- Minimum Age: None
- Maximum Age: 10 Days
- Healthy Volunteers: f

Study Arms:
- High Dose Milrinone (Type: EXPERIMENTAL): Subjects will receive a bolus intravenous (IV) infusion of 50 mcg/kg/min of milrinone lactate over 1 hour followed by a continuous IV infusion of 0.5 mcg/kg/min milrinone lactate over 24 hours. After completion of infusion, subjects will be monitored for an additional 24 hours.
- Low Dose Milrinone (Type: EXPERIMENTAL): Subjects will receive a bolus intravenous (IV) infusion of 20 mcg/kg/min of milrinone lactate over 1 hour followed by a continuous IV infusion of 0.2 mcg/kg/min milrinone lactate over 24 hours. After completion of infusion, subjects will be monitored for an additional 24 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).